Bilateral vestibulopathy in anti-IgLON5 disease

Christoph Helmchen; Klaus Peter Wandinger; Armin Steffen; Thomas F. Münte; Norbert Brüggemann

doi:10.1007/s00415-020-10386-5

Bilateral vestibulopathy in anti-IgLON5 disease

Christoph Helmchen^*, Klaus Peter Wandinger, Armin Steffen, Thomas F. Münte, Norbert Brüggemann

^*Korrespondierende/r Autor/-in für diese Arbeit

Originalsprache	Englisch
Zeitschrift	Journal of Neurology
Jahrgang	268
Ausgabenummer	3
Seiten (von - bis)	1114-1116
Seitenumfang	3
ISSN	0340-5354
DOIs	https://doi.org/10.1007/s00415-020-10386-5
Publikationsstatus	Veröffentlicht - 03.2021

Fördermittel

C. Helmchen received honoraria from Sensorion, Heel, Schwabe, Pierre Fabre. K.P.Wandinger reports no disclosures relevant to the manuscript; A. Steffen is a study investigator and received honoraria and travel expenses for invited talks on behalf of Inspire Medical, Inc. He serves as a consultant for Merz Pharmaceuticals and received honoraria for expert meetings from Proveca Ltd. T.F. Münte is funded by the DFG (MU1311/16-2, 17-1, 20-1, CRC/TR296) and BMBF (01GJ1303B). N. Brüggemann received speaker’s honoraria from Grünenthal, UCB, Abbvie and Teva. He served as a consultant for Censa Pharmaceuticals and Centogene. He received non-financial support from Bayer. NB is funded by the DFG (BR4328.2-2, GRK1957), the Collaborative Center for X-linked Dystonia-Parkinsonism and the Else-Kröner Fresenius-Stiftung (HA17_2017).

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen
SDG 10 – Weniger Ungleichheiten

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Dokumente

10.1007/s00415-020-10386-5

Weitere Links

Zitieren

@article{5253e9693f0d4db69169de84a1c83847,

title = "Bilateral vestibulopathy in anti-IgLON5 disease",

author = "Christoph Helmchen and Wandinger, \{Klaus Peter\} and Armin Steffen and M{\"u}nte, \{Thomas F.\} and Norbert Br{\"u}ggemann",

note = "Funding Information: C. Helmchen received honoraria from Sensorion, Heel, Schwabe, Pierre Fabre. K.P.Wandinger reports no disclosures relevant to the manuscript; A. Steffen is a study investigator and received honoraria and travel expenses for invited talks on behalf of Inspire Medical, Inc. He serves as a consultant for Merz Pharmaceuticals and received honoraria for expert meetings from Proveca Ltd. T.F. M{\"u}nte is funded by the DFG (MU1311/16-2, 17-1, 20-1, CRC/TR296) and BMBF (01GJ1303B). N. Br{\"u}ggemann received speaker{\textquoteright}s honoraria from Gr{\"u}nenthal, UCB, Abbvie and Teva. He served as a consultant for Censa Pharmaceuticals and Centogene. He received non-financial support from Bayer. NB is funded by the DFG (BR4328.2-2, GRK1957), the Collaborative Center for X-linked Dystonia-Parkinsonism and the Else-Kr{\"o}ner Fresenius-Stiftung (HA17\_2017). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = mar,

doi = "10.1007/s00415-020-10386-5",

language = "English",

volume = "268",

pages = "1114--1116",

journal = "Journal of Neurology",

issn = "0340-5354",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

TY - JOUR

T1 - Bilateral vestibulopathy in anti-IgLON5 disease

AU - Helmchen, Christoph

AU - Wandinger, Klaus Peter

AU - Steffen, Armin

AU - Münte, Thomas F.

AU - Brüggemann, Norbert

N1 - Funding Information: C. Helmchen received honoraria from Sensorion, Heel, Schwabe, Pierre Fabre. K.P.Wandinger reports no disclosures relevant to the manuscript; A. Steffen is a study investigator and received honoraria and travel expenses for invited talks on behalf of Inspire Medical, Inc. He serves as a consultant for Merz Pharmaceuticals and received honoraria for expert meetings from Proveca Ltd. T.F. Münte is funded by the DFG (MU1311/16-2, 17-1, 20-1, CRC/TR296) and BMBF (01GJ1303B). N. Brüggemann received speaker’s honoraria from Grünenthal, UCB, Abbvie and Teva. He served as a consultant for Censa Pharmaceuticals and Centogene. He received non-financial support from Bayer. NB is funded by the DFG (BR4328.2-2, GRK1957), the Collaborative Center for X-linked Dystonia-Parkinsonism and the Else-Kröner Fresenius-Stiftung (HA17_2017). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/3

Y1 - 2021/3

UR - https://www.scopus.com/pages/publications/85099605976

UR - https://www.mendeley.com/catalogue/cd393028-c6ff-3604-9579-29875d524581/

U2 - 10.1007/s00415-020-10386-5

DO - 10.1007/s00415-020-10386-5

M3 - Journal articles

C2 - 33484327

AN - SCOPUS:85099605976

SN - 0340-5354

VL - 268

SP - 1114

EP - 1116

JO - Journal of Neurology

JF - Journal of Neurology

IS - 3

ER -